CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07Submission of Matters to a Vote of Security Holders.
CytomX Therapeutics, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders (the Annual Meeting) on June 20, 2017. On
the April 28, 2017 record date, there were 36,743,701 shares of
the Companys common stock outstanding with each such share being
entitled to one vote per share.
At the Annual Meeting, 28,934,990 shares of the Companys common
stock were voted in person or by proxy for the two proposals set
forth below, each of which is described in the Companys
Definitive Proxy Statement on Schedule 14A filed with the U.S.
Securities and Exchange Commission on May 9, 2017.
Proposal 1. The Companys stockholders elected the Class II
director nominees below to the Companys Board of Directors to
hold office until the 2020 Annual Meeting of Stockholders and
until their respective successors are duly elected and qualified,
or the earlier of their death, resignation or removal.
|
NOMINEE |
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|||
|
Neil Exter |
24,473,817 |
634,208 |
6,776 |
3,820,189 |
|||
|
Frederick W. Gluck |
24,485,859 |
627,916 |
1,026 |
3,820,189 |
|||
|
Matthew P. Young |
23,835,087 |
1,272,838 |
6,876 |
3,820,189 |
|||
Proposal 2. The Companys stockholders ratified the selection of
PricewaterhouseCoopers LLP as the independent registered public
accounting firm of the Company for its fiscal year ending
December 31, 2017.
|
FOR |
AGAINST |
ABSTAIN |
BROKER NON-VOTES |
|
28,924,579 |
4,100 |
6,311 |
About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.
